Steroids in Lupus: Enemies or Allies
- PMID: 37297834
- PMCID: PMC10253271
- DOI: 10.3390/jcm12113639
Steroids in Lupus: Enemies or Allies
Abstract
Glucocorticoids are the gold standard treatment for reducing immune activation and inflammation in a wide range of inflammatory and systemic autoimmune diseases. Glucocorticoids have potent and fast actions that quickly relieve some symptoms and lower mortality in some life-threatening conditions, but they also have side effects that limit the duration of treatment and the dose used. Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the involvement of numerous organs and systems and the production of autoantibodies. Most current treatments include the use of corticosteroids and immunosuppressive medications. Glucocorticoids in SLE have been classically used not only to induce remission or treat an acute situation but also as maintenance therapy. During the last decades, new approaches to managing SLE have emerged, but corticosteroids continue to be part of all therapeutic regimes. There is more and more evidence about the side effects related to the use (or abuse) of steroids and their relationship with the accrual damage. In this manuscript, we try to make a critical review of the published literature about the benefit and side effects/damage that can be attributed to the use of glucocorticoids.
Keywords: acrual damage; dose; side effectis; treatment duration.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
[Psychiatric manifestations of lupus erythematosus systemic and Sjogren's syndrome].Encephale. 2001 Nov-Dec;27(6):588-99. Encephale. 2001. PMID: 11865567 French.
-
Withdrawal of therapy in non-renal systemic lupus erythematosus: is this an achievable goal?Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl 78):S71-4. Epub 2013 Oct 4. Clin Exp Rheumatol. 2013. PMID: 24129142 Review.
-
New directions in the treatment of systemic lupus erythematosus.Curr Med Res Opin. 2009 Jun;25(6):1501-14. doi: 10.1185/03007990902929104. Curr Med Res Opin. 2009. PMID: 19435401 Review.
-
Systemic lupus erythematosus-related acute pancreatitis.Lupus. 2021 Jan;30(1):5-14. doi: 10.1177/0961203320978515. Epub 2020 Dec 13. Lupus. 2021. PMID: 33307986 Review.
-
[Treatment of systemic lupus erythematosus: myths, certainties and doubts].Med Clin (Barc). 2013 Dec 21;141(12):533-42. doi: 10.1016/j.medcli.2013.02.014. Epub 2013 Apr 23. Med Clin (Barc). 2013. PMID: 23622892 Review. Spanish.
Cited by
-
Effectiveness of Belimumab for Glucocorticoid Discontinuation in Juvenile-Onset Lupus Nephritis.Indian J Nephrol. 2025 Jan-Feb;35(1):85-87. doi: 10.25259/IJN_444_2024. Epub 2024 Oct 4. Indian J Nephrol. 2025. PMID: 39872261 Free PMC article.
-
Evolving Treatment Strategies for Systemic Lupus Erythematosus in Clinical Practice: A Narrative Review.Cureus. 2024 Dec 3;16(12):e75062. doi: 10.7759/cureus.75062. eCollection 2024 Dec. Cureus. 2024. PMID: 39759646 Free PMC article. Review.
-
Cryptogenic Organizing Pneumonia Is Associated With Increased Mortality Risk in Hospitalizations for Systemic Lupus Erythematosus (SLE): A National Inpatient Sample Analysis.Cureus. 2024 Sep 22;16(9):e69901. doi: 10.7759/cureus.69901. eCollection 2024 Sep. Cureus. 2024. PMID: 39439634 Free PMC article.
-
CAR T cell therapy for refractory pediatric systemic lupus erythematosus: a new era of hope?Pediatr Rheumatol Online J. 2024 Aug 8;22(1):72. doi: 10.1186/s12969-024-00990-4. Pediatr Rheumatol Online J. 2024. PMID: 39118067 Free PMC article. Review.
-
Effectiveness and safety of telitacicept in patients with systemic lupus erythematosus: a single center, retrospective, real-world study.Clin Rheumatol. 2025 Mar;44(3):1113-1122. doi: 10.1007/s10067-025-07348-5. Epub 2025 Feb 4. Clin Rheumatol. 2025. PMID: 39903405
References
-
- Buttgereit F., da Silva J.A.P., Boers M., Burmester G.-R., Cutolo M., Jacobs J., Kirwan J., Köhler L., van Riel P.L.C.M., Vischer T., et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: Current questions and tentative answers in rheumatology. Ann. Rheum. Dis. 2002;61:718–722. doi: 10.1136/ard.61.8.718. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources